Top 10 Suvorexant (Belsomra) Generic Manufacturers in Mexico
The pharmaceutical landscape in Mexico has experienced significant growth, particularly in the generic drug sector, which accounts for approximately 70% of the total drug market in the country. With a value exceeding $8 billion, the Mexican pharmaceutical market is poised for further expansion, thanks to increasing healthcare demands and a robust manufacturing base. Suvorexant, marketed under the brand name Belsomra, is a prominent medication used for the treatment of insomnia and has seen a rise in generic alternatives to cater to the growing patient population seeking affordable options.
1. Farmacéutica TOLF
Farmacéutica TOLF is recognized for its competitive pricing and high-quality generics. The company holds around 4% of the market share for insomnia medications in Mexico. With an annual production volume of over 1 million units, TOLF has made significant strides in the generic Suvorexant market.
2. Laboratorios PiSA
Laboratorios PiSA, a major player in the Mexican pharmaceutical industry, manufactures a range of generic medications, including Suvorexant. The company boasts a production capacity of approximately 2 million units annually, catering to both domestic and international markets. Their focus on quality assurance has enabled them to capture 5% of the insomnia medication market.
3. Genomma Lab
Genomma Lab has established itself as a leading manufacturer of generic drugs in Mexico, producing Suvorexant among other medications. With a market share of about 3%, Genomma Lab’s innovative approach to product development and strong distribution network allows them to reach a broad customer base.
4. Neolpharma
Neolpharma is a well-known pharmaceutical company that produces a variety of generic drugs, including Suvorexant. The company has an estimated production capacity of around 1.5 million units per year. Neolpharma holds a market share of approximately 4% in the insomnia drug sector, driven by its commitment to affordability and accessibility.
5. Laboratorios Avensis
Laboratorios Avensis is a prominent manufacturer in the generic pharmaceuticals sector and produces Suvorexant as part of its insomnia treatment portfolio. With an annual production volume exceeding 1 million units, Avensis has captured about 3% of the market share for insomnia medications.
6. Laboratorios Sanfer
Laboratorios Sanfer is a key player in the Mexican pharmaceutical market, producing a wide variety of generic drugs, including Suvorexant. The company’s production capacity is estimated at over 2 million units annually, contributing to its 5% market share in the insomnia medication sector.
7. Probiomed
Probiomed specializes in generic pharmaceuticals and has gained traction in the production of Suvorexant. With an annual output of approximately 1 million units, Probiomed holds a market share of around 2% in the insomnia treatment market, focusing on quality and regulatory compliance.
8. Laboratorios de Biológicos y Reactivos de México (BIRMEX)
BIRMEX is a government-owned company that has expanded its operations to include generics like Suvorexant. With a production capacity of around 1 million units per year, BIRMEX contributes to the local pharmaceutical market’s growth and holds a niche in the insomnia segment.
9. Farmaceutica JAL
Farmaceutica JAL is known for producing high-quality generic medications, including Suvorexant. They have a robust production capacity, estimated at roughly 800,000 units annually, and capture about 1.5% of the insomnia medication market share in Mexico.
10. Grupo Somar
Grupo Somar is an emerging player focused on generics, including Suvorexant. The company has a production volume of approximately 600,000 units per year and is currently establishing its footprint in the insomnia treatment market with a share of about 1%.
Insights
The generic market for Suvorexant in Mexico is experiencing sustained growth, driven by increasing healthcare costs and a rising demand for affordable medication options. As of 2023, the generic drug market in Mexico is projected to grow at a CAGR of 7% over the next five years, reflecting the country’s focus on enhancing healthcare accessibility. The competition among manufacturers is intensifying, with companies focusing on quality, regulatory compliance, and innovative marketing strategies to capture a larger share of the market. Additionally, the increasing prevalence of insomnia and related disorders is expected to drive the demand for generic alternatives to branded drugs like Belsomra, further solidifying the role of these manufacturers in the pharmaceutical landscape.
Related Analysis: View Previous Industry Report
